TITLE

Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice

AUTHOR(S)
Li, L.; Yuan, Y.-Z.; Lu, J.; Xia, L.; Zhu, Y.; Zhang, Y.-P.; Qiao, M-M.
PUB. DATE
February 2006
SOURCE
Gut;Feb2006, Vol. 55 Issue 2, p259
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Tumour growth is angiogenesis dependent and antiangiogenesis therapy may represent a promising therapeutic option. Aims: To evaluate the inhibitory effect of vasostotin gene mediated by a replication deficient recombinant adenovirus (Ad) on human pancreatic cancer in vivo and to investigate the mechanism of action of vasostotin. Methods: Human umbilical vein endothelium derived ECV304 cells were infected with Ad-vasostatin and Ad-lacZ, and compared with phosphate buffered saline (PBS). MTT (3,-[4,5-dimethylthiozol-2-yl]-2,5- diphenyltetrazolium bromide) assay was used to estimate the proliferation of ECV304 cells; tube formation assay and choriallantoic membrane assay were used to evaluate angiogenesis in vivo and in vitro. Xenografted nude mice with pancreatic cancer were established to observe in vivo tumour growth suppression. Microvessel density revealed by CD31 immunohistochemical staining was measured. Results: Growth and tube formation of ECV304 cells infected with Ad-vasostotin were suppressed significantly compared with cells infected with Ad-lacZ or cells treated with PBS. Neavoscularisofion in the Ad-vasostatin group was less than that in the PBS and Ad-lacZ groups, based on chorioallantoic membrane results. Volumes of pancreatic tumours in the Ad-vasostotin group were significantly smaller than those in the PBS and Ad-lacZ groups at the end of the treatment period. Microvessel density in the Ad- vasostotin group was significantly lower than that in the Ad-lacZ and PBS groups. Conclusion: The vasostatin gene mediated by odenovirus is efficient for gene therapy for pancreatic carcinoma. Suppression of vasostatin on proliferation of vascular endothelium cells and angiogenesis may account for its effect.
ACCESSION #
19552437

 

Related Articles

  • Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma. Ternovoi, Vladimir V.; Curiel, David T.; Smith, Bruce F.; Siegal, Gene P. // Laboratory Investigation (00236837);Aug2006, Vol. 86 Issue 8, p748 

    The clinical outcome for osteosarcoma (OS) remains discouraging despite efforts to optimize treatment using conventional modalities including surgery, radiotherapy and chemotherapy. Novel therapeutic approaches based on our expanding understanding of the mechanisms of tumor cell killing have the...

  • Adenoviral Vectors for Cancer Gene Therapy. Wenli Zhao, S.; Kobayashi, Masanobu; Hosokawa, Masuo; Seth, Prem // Current Genomics;Jun2002, Vol. 3 Issue 3, p163 

    Cancer gene therapy is considered a very viable approach for the treatment of cancer. The basic idea is to introduce the therapeutic gene, often in the form of a foreign cDNA, into the cancer or other appropriate target cells. For gene delivery purposes, several viral and non-viral vectors have...

  • Antitumor efficacy of AAV-mediated systemic delivery of interferon-β. Streck, C. J.; Dickson, P. V.; Ng, C. Y. C.; Zhou, J.; Hall, M. M.; Gray, J. T.; Nathwani, A. C.; Davidoff, A. M. // Cancer Gene Therapy;Jan2006, Vol. 13 Issue 1, p99 

    Type I interferons (α/β) have significant antitumor activity although their short half-life and systemic side effects have limited their clinical utility. An alternative dosing schedule of continuous, low-level delivery, as is achieved by gene therapy, rather than intermittent, high...

  • 656. Combined Oncolysis and Anti-Angiogenesis Gene Therapy Using a Herpes Simplex Virus Expressing Endostatin in a Murine Lung Cancer Model. Lanuti, Michael; Goodwin, Jonathan M.; Tanabe, Kenneth K. // Molecular Therapy;Jun2006, Vol. 13, pS252 

    Malignant pleural mesothelioma is unresponsive to most forms of therapy and often recurs after multimodality regimens. Oncolytic gene therapy using a replication-conditional Herpes virus in combination with anti-angiogenesis strategies may provide a novel adjunct to the treatment of this...

  • 656. Combined Oncolysis and Anti-Angiogenesis Gene Therapy Using a Herpes Simplex Virus Expressing Endostatin in a Murine Lung Cancer Model. Lanuti, Michael; Goodwin, Jonathan M.; Tanabe, Kenneth K. // Molecular Therapy;Jun2006, Vol. 13, pS252 

    Malignant pleural mesothelioma is unresponsive to most forms of therapy and often recurs after multimodality regimens. Oncolytic gene therapy using a replication-conditional Herpes virus in combination with anti-angiogenesis strategies may provide a novel adjunct to the treatment of this...

  • Combining cellular and gene therapy approaches for treatment of intracranial tumors. Hickey, Michelle J.; Kasahara, Noriyuki; Mueller, Barbara M.; Kruse, Carol A. // OncoImmunology;Oct2013, Vol. 2 Issue 10, pe25989-1 

    New treatments are needed for brain metastasis, which is associated with high morbidity and mortality. Two novel cellular and gene therapy modalities were evaluated in xenograft models for human breast cancer. The individual and especially the combined treatments with alloreactive cytotoxic T...

  • Derivation of a Triple Mosaic Adenovirus for Cancer Gene Therapy. Yizhe Tang; Hongju Wu; Ugai, Hideyo; Matthews, Qiana L.; Curiel, David T. // PLoS ONE;2009, Vol. 4 Issue 12, p1 

    A safe and efficacious cancer medicine is necessary due to the increasing population of cancer patients whose particular diseases cannot be cured by the currently available treatment. Adenoviral (Ad) vectors represent a promising therapeutic medicine for human cancer therapy. However, several...

  • Selective Intratumoral Amplification of an Antiangiogenic Vector by an Oncolytic Virus Produces Enhanced Antivascular and Anti-tumor Efficacy. Thorne, Stephen H.; Tam, Betty Y.Y.; Kirn, David H.; Contag, Christopher H.; Kuo, Calvin J. // Molecular Therapy;May2006, Vol. 13 Issue 5, p938 

    The development of effective cancer therapy will require the simultaneous targeting of multiple steps in tumor development. We have previously described an antiangiogenic gene therapy vector, Ad Flk1-Fc, which expresses a soluble VEGF receptor capable of inhibiting tumor angiogenesis and growth....

  • Biomolecular strategies for therapeutic intervention in cancer. Giordano, Antonio; Maio, Michele // Oncogene;9/29/2003 Review, Vol. 22 Issue 42, p6469 

    Introduces a series of articles on biomolecular strategies for therapeutic intervention in cancer.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics